SLC13A2 and metabolic dysfunction-associated steatotic liver disease: Recent studies have indicated that the increased activity of NaCT contributes to certain conditions, such as obesity, non-alcoholic fatty liver disease (NAFLD), high-fat diet treatment in rhesus monkeys, and exposure to xenobiotics in human and rat hepatocytes [13,14,15,16,17,43].